{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:28:44Z","timestamp":1793694524316,"version":"4.5.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00120-026-02943-z","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:49:43Z","timestamp":1792144183000},"page":"1207-1211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zusatznutzen uroonkologischer Systemtherapien\u00a0\u2013 droht nach Wegfall der Praxisbesonderheit Regressgefahr?","Added benefits of systemic uro-oncological therapies\u2014risk of recourse following elimination of the special practice designation"],"prefix":"10.1007","volume":"65","author":[{"given":"Manfred","family":"Johannsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Zillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Klier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Doehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulafah","family":"El-Khadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"2943_CR1","unstructured":"https:\/\/www.gkv-spitzenverband.de\/media\/dokumente\/krankenversicherung_1\/aerztliche_versorgung\/bundesmantelvertrag_1\/bmv_anlagen\/2026-07-01_Onkologie-Vereinbarung.pdf"},{"key":"2943_CR2","unstructured":"https:\/\/www.kvberlin.de\/fuer-praxen\/alles-fuer-den-praxisalltag\/verordnung\/wirtschaftlichkeitspruefung#c4108"},{"key":"2943_CR3","unstructured":"https:\/\/www.aerzteblatt.de\/archiv\/pdf\/00655c43-5dbb-426b-a8c6-0c6300ae1335"},{"key":"2943_CR4","unstructured":"https:\/\/www.iqwig.de\/presse\/mediathek\/grafiken\/das-amnog-verfahren\/"},{"key":"2943_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100171","volume":"9","author":"CG Urzua-Traslavina","year":"2025","unstructured":"Urzua-Traslavina\u00a0CG, Latino\u00a0NJ, Galotti\u00a0M, Cherny\u00a0NI, Oosting\u00a0SF, de Vries\u00a0EGE, Fehrmann\u00a0RSN (2025) The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) visualisation: picturing the evidence of clinical benefit of clinical trial data. ESMO Real World Data Digit Oncol 9:100171. https:\/\/doi.org\/10.1016\/j.esmorw.2025.100171","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"2943_CR6","unstructured":"https:\/\/www.g-ba.de\/downloads\/39-261-5954\/2023-04-06_AM-RL-XII_Relugolix_D-873_BAnz.pdf"},{"key":"2943_CR7","unstructured":"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2119115"},{"key":"2943_CR8","unstructured":"https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/arzneimittel\/verhandlungen_nach_amnog\/ebv_130b\/ebv_nach_130b.jsp?submitted=true&sort=substance&descending=0&searchterm=&status=Alle&specialFeature=true"},{"key":"2943_CR9","unstructured":"https:\/\/urologie-gestalten.de\/downloads\/"},{"key":"2943_CR10","unstructured":"https:\/\/www.kvberlin.de\/fuer-praxen\/alles-fuer-den-praxisalltag\/verordnung\/wirtschaftlichkeitspruefung"},{"key":"2943_CR11","unstructured":"https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/fruehe-nutzenbewertung\/cabazitaxel\/cabazitaxel-dgho-stellungnahme-20120205.pdf"},{"key":"2943_CR12","unstructured":"https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/fruehe-nutzenbewertung\/axitinib\/axitinib-dgho-stellungnahme-20130122.pdf"},{"key":"2943_CR13","unstructured":"https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/fruehe-nutzenbewertung\/niraparib_abirateron\/niraparib-abirateron-prostatakarzinom-dgho-dgu-20260705.pdf"},{"key":"2943_CR14","unstructured":"https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/fruehe-nutzenbewertung\/nivolumab\/nivolumab-urothelkarzinom-stellungnahme-20260407.pdf"},{"key":"2943_CR15","unstructured":"https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/fruehe-nutzenbewertung\/nivolumab\/nivolumab-neues-anwendungsgebiet-nierenzellkarzinom-dgho-stellungnahme-20160822.pdf"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02943-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02943-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02943-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:02:11Z","timestamp":1793692931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02943-z"}},"subtitle":["Teil\u00a01: Prostatakarzinom","Part\u00a01: prostate cancer"],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2943"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02943-z","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"8 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Johannsen, R.\u00a0Zillmann, J.\u00a0Klier, C.\u00a0Doehn und S.\u00a0El-Khadra geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}